MMS Q1 2026 Earnings EPS Beats Estimates Amid Cautious Market Response NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43 DTIL Q1 2026 Earnings EPS Misses Estimates as Gene Editing Pipeline Progress Takes Center Stage AGCO Q1 2026 Earnings Strong Profit Beat Bolsters Investor Sentiment After Challenging Quarter ALIT Q1 2026 Earnings EPS Surprises 34 Above Estimates Stock Edges Higher CEVA Q1 2026 Earnings EPS Surprise Drives Positive Market Response